Pinnacle Financial Partners, Inc.
Position in GALT — Galectin Therapeutics Inc
CIK 2082866
ATLANTA, GA
Position in GALT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$193,256
+$77,053 QoQ
Shares Held
41,650
0.0% QoQ
Ownership
0.041%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#40
of 98 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GALT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pinnacle Financial Partners, Inc. holds $51,363,059 across 17 Biotechnology names. GALT ranks #16 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,848 | $9,859,095 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
20,243 | $7,523,715 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
89,881 | $7,034,985 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
22,842 | $5,591,036 | |
| 5 | RPRX |
Royalty Pharma plc
|
86,237 | $4,835,307 | |
| 6 | SNDX |
Syndax Pharmaceuticals Inc
|
217,173 | $4,747,401 | |
| 7 | VSTM |
Verastem, Inc.
|
1,086,440 | $4,150,200 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
35,081 | $2,007,334 |
All Filings in GALT
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $193,256 | 41,650 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $116,203 | 41,650 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $199,680 | 48,000 | Shares | Defined | 2026-02-18 | |
| No filing history on record for this holder in this stock. | ||||||